DK3423060T3 - Imatinib til anvendelse til behandling af slagtilfælde - Google Patents
Imatinib til anvendelse til behandling af slagtilfælde Download PDFInfo
- Publication number
- DK3423060T3 DK3423060T3 DK17760399.0T DK17760399T DK3423060T3 DK 3423060 T3 DK3423060 T3 DK 3423060T3 DK 17760399 T DK17760399 T DK 17760399T DK 3423060 T3 DK3423060 T3 DK 3423060T3
- Authority
- DK
- Denmark
- Prior art keywords
- imatinib
- stroke
- treatment
- Prior art date
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title 1
- 208000006011 Stroke Diseases 0.000 title 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title 1
- 229960002411 imatinib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (en) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
| PCT/SE2017/050183 WO2017151043A1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3423060T3 true DK3423060T3 (da) | 2021-10-25 |
Family
ID=59744327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17760399.0T DK3423060T3 (da) | 2016-02-29 | 2017-02-27 | Imatinib til anvendelse til behandling af slagtilfælde |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953010B2 (da) |
| EP (1) | EP3423060B1 (da) |
| JP (1) | JP6914957B2 (da) |
| CN (2) | CN108697711A (da) |
| AU (1) | AU2017227515B2 (da) |
| DK (1) | DK3423060T3 (da) |
| ES (1) | ES2895432T3 (da) |
| HR (1) | HRP20211621T1 (da) |
| HU (1) | HUE056798T2 (da) |
| LT (1) | LT3423060T (da) |
| PL (1) | PL3423060T3 (da) |
| PT (1) | PT3423060T (da) |
| RS (1) | RS62465B1 (da) |
| RU (1) | RU2739382C1 (da) |
| SE (1) | SE539450C2 (da) |
| SI (1) | SI3423060T1 (da) |
| WO (1) | WO2017151043A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| CN114306342B (zh) * | 2020-09-30 | 2024-06-28 | 江苏先声药业有限公司 | 一种注射用伊马替尼盐的药物组合物及其制备方法 |
| JP2024544508A (ja) * | 2021-11-09 | 2024-12-03 | トゥルーバインディング，インコーポレイテッド | 心臓血管疾患を治療または阻害する方法 |
| EP4311539A1 (en) | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| AU2007240429A1 (en) | 2006-04-17 | 2007-11-01 | Ludwig Institute For Cancer Research Ltd | Methods and compositions for modulation of blood-neural barrier |
| US7977348B2 (en) | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
| WO2008057291A2 (en) * | 2006-10-26 | 2008-05-15 | Sicor Inc. | Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US9289459B2 (en) * | 2009-03-27 | 2016-03-22 | Moleac Pte. Ltd. | Therapy for promoting cell growth |
-
2016
- 2016-02-29 SE SE1650260A patent/SE539450C2/en not_active IP Right Cessation
-
2017
- 2017-02-27 US US16/080,529 patent/US10953010B2/en active Active
- 2017-02-27 WO PCT/SE2017/050183 patent/WO2017151043A1/en not_active Ceased
- 2017-02-27 SI SI201730931T patent/SI3423060T1/sl unknown
- 2017-02-27 CN CN201780013732.6A patent/CN108697711A/zh active Pending
- 2017-02-27 DK DK17760399.0T patent/DK3423060T3/da active
- 2017-02-27 JP JP2018545843A patent/JP6914957B2/ja active Active
- 2017-02-27 LT LTEPPCT/SE2017/050183T patent/LT3423060T/lt unknown
- 2017-02-27 EP EP17760399.0A patent/EP3423060B1/en active Active
- 2017-02-27 CN CN202411509669.3A patent/CN119523986A/zh active Pending
- 2017-02-27 HR HRP20211621TT patent/HRP20211621T1/hr unknown
- 2017-02-27 ES ES17760399T patent/ES2895432T3/es active Active
- 2017-02-27 RS RS20211286A patent/RS62465B1/sr unknown
- 2017-02-27 RU RU2019122730A patent/RU2739382C1/ru active
- 2017-02-27 PT PT177603990T patent/PT3423060T/pt unknown
- 2017-02-27 AU AU2017227515A patent/AU2017227515B2/en active Active
- 2017-02-27 PL PL17760399T patent/PL3423060T3/pl unknown
- 2017-02-27 HU HUE17760399A patent/HUE056798T2/hu unknown
-
2021
- 2021-02-26 US US17/186,303 patent/US20210236488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20211621T1 (hr) | 2022-02-04 |
| EP3423060A4 (en) | 2020-01-01 |
| AU2017227515B2 (en) | 2022-03-24 |
| LT3423060T (lt) | 2021-11-10 |
| US10953010B2 (en) | 2021-03-23 |
| ES2895432T3 (es) | 2022-02-21 |
| PL3423060T3 (pl) | 2022-01-10 |
| SE1650260A1 (en) | 2017-08-30 |
| JP2019507165A (ja) | 2019-03-14 |
| SE539450C2 (en) | 2017-09-26 |
| RU2739382C1 (ru) | 2020-12-23 |
| EP3423060A1 (en) | 2019-01-09 |
| AU2017227515A1 (en) | 2018-08-30 |
| CN108697711A (zh) | 2018-10-23 |
| JP6914957B2 (ja) | 2021-08-04 |
| RS62465B1 (sr) | 2021-11-30 |
| HUE056798T2 (hu) | 2022-03-28 |
| EP3423060B1 (en) | 2021-07-21 |
| SI3423060T1 (sl) | 2021-11-30 |
| WO2017151043A1 (en) | 2017-09-08 |
| CN119523986A (zh) | 2025-02-28 |
| PT3423060T (pt) | 2021-10-20 |
| US20190030030A1 (en) | 2019-01-31 |
| US20210236488A1 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3182975T3 (da) | Tabletter med høj doseringsstyrke af rucaparib | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| EP3564335A4 (en) | SURFACE TREATMENT AGENT | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3496551T3 (da) | Flydende allulosesammensætning | |
| EP3499651A4 (en) | Connector | |
| EP3506842A4 (en) | osteotome | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3556383T3 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
| DK3522904T3 (da) | Flydende sammensætning til anvendelse i behandlingen af gastroesophageal reflux | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3423060T3 (da) | Imatinib til anvendelse til behandling af slagtilfælde |